New chronic nerve pain treatment moves to next phase

Tat-P4-(C5)2, chronic pain treatment, new pain drug, arthritis research, arthritis digestA compound designed by a team from the University of Copenhagen seems to achieve complete pain relief and have no side effects, the group explains in EMBO Molecular Medicine.

Up to 10% of the world’s population suffers from chronic pain originating from nerves that have been damaged.

The compound is a so-called peptide called Tat-P4-(C5)2 that affects the nerve changes that pose a problem and cause the pain. It has been tested in mice and is ready for clinical trials in people.

“The compound works very efficiently, and we do not see any side effects,” says Kenneth Lindegaard Madsen who is involved in the work. “We can administer this peptide and obtain complete pain relief in the mouse model we have used, without the lethargic effect that characterises existing pain-relieving drugs.”\

Arthritis Digest Magazine was selected by Feedspot as one of the Top 5 Arthritis Blogs on the internet in 2019.

For more in-depth features, interviews and information, subscribe to Arthritis Digest magazine, a popular title that’s published six times a year. Click here for the digital version or tel 0845 643 8470 to order your had copy. You’ll know what your doctor is talking about, what new drugs are in the pipeline and be up to date on helpful products.